Global Adrenoleukodystrophy Treatment Market Growth (Status and Outlook) 2023-2029

February 2023 | 121 pages | ID: G58896F17D8BEN
LP Information

US$ 3,660.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
The report requires updating with new data and is sent in 48 hours after order is placed.

Adrenoleukodystrophy refers to a rare genetic condition that causes the buildup of long chain fatty acids (VLCFAs) in the brain. ALD is led by a mutation in the ABCD1 gene on the X chromosome. The three types of adrenoleukodystrophy including Adrenomyelopathy, Childhood cerebral ALD and Addison’s disease. Childhood cerebral ALD is known to progress rapidly in children between the ages of 3 and 10.

LPI (LP Information)' newest research report, the “Adrenoleukodystrophy Treatment Industry Forecast” looks at past sales and reviews total world Adrenoleukodystrophy Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Adrenoleukodystrophy Treatment sales for 2023 through 2029. With Adrenoleukodystrophy Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Adrenoleukodystrophy Treatment industry.

This Insight Report provides a comprehensive analysis of the global Adrenoleukodystrophy Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Adrenoleukodystrophy Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Adrenoleukodystrophy Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Adrenoleukodystrophy Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Adrenoleukodystrophy Treatment.

The global Adrenoleukodystrophy Treatment market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Adrenoleukodystrophy Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Adrenoleukodystrophy Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Adrenoleukodystrophy Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Adrenoleukodystrophy Treatment players cover bluebird bio, Orpheris, MedDay Pharmaceuticals, MINORYX THERAPEUTICS SL, Pfizer, Amgen, AstraZeneca, Abbott and agtc, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Adrenoleukodystrophy Treatment market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
  • Oral Drugs
  • Parenteral Drugs
Segmentation by application
  • Hospital
  • Clinic
  • Home Care
This report also splits the market by region:
  • Americas
    • United States
    • Canada
    • Mexico
    • Brazil
  • APAC
    • China
    • Japan
    • Korea
    • Southeast Asia
    • India
    • Australia
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Russia
  • Middle East & Africa
    • Egypt
    • South Africa
    • Israel
    • Turkey
    • GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
  • bluebird bio
  • Orpheris
  • MedDay Pharmaceuticals
  • MINORYX THERAPEUTICS SL
  • Pfizer
  • Amgen
  • AstraZeneca
  • Abbott
  • agtc
  • ReceptoPharm
  • The Myelin Project
  • SOM Biotech
  • Viking Therapeutics
  • Nutra Pharma Corporation
  • Genetix Biotech
  • Magenta Therapeutics
  • NeuroVia
  • Novartis
  • CELGENE CORPORATION
  • Jazz Pharmaceuticals
  • Sanofi
1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Adrenoleukodystrophy Treatment Market Size 2018-2029
  2.1.2 Adrenoleukodystrophy Treatment Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Adrenoleukodystrophy Treatment Segment by Type
  2.2.1 Oral Drugs
  2.2.2 Parenteral Drugs
2.3 Adrenoleukodystrophy Treatment Market Size by Type
  2.3.1 Adrenoleukodystrophy Treatment Market Size CAGR by Type (2018 VS 2022 VS 2029)
  2.3.2 Global Adrenoleukodystrophy Treatment Market Size Market Share by Type (2018-2023)
2.4 Adrenoleukodystrophy Treatment Segment by Application
  2.4.1 Hospital
  2.4.2 Clinic
  2.4.3 Home Care
2.5 Adrenoleukodystrophy Treatment Market Size by Application
  2.5.1 Adrenoleukodystrophy Treatment Market Size CAGR by Application (2018 VS 2022 VS 2029)
  2.5.2 Global Adrenoleukodystrophy Treatment Market Size Market Share by Application (2018-2023)

3 ADRENOLEUKODYSTROPHY TREATMENT MARKET SIZE BY PLAYER

3.1 Adrenoleukodystrophy Treatment Market Size Market Share by Players
  3.1.1 Global Adrenoleukodystrophy Treatment Revenue by Players (2018-2023)
  3.1.2 Global Adrenoleukodystrophy Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Adrenoleukodystrophy Treatment Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
  3.3.1 Competition Landscape Analysis
  3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion

4 ADRENOLEUKODYSTROPHY TREATMENT BY REGIONS

4.1 Adrenoleukodystrophy Treatment Market Size by Regions (2018-2023)
4.2 Americas Adrenoleukodystrophy Treatment Market Size Growth (2018-2023)
4.3 APAC Adrenoleukodystrophy Treatment Market Size Growth (2018-2023)
4.4 Europe Adrenoleukodystrophy Treatment Market Size Growth (2018-2023)
4.5 Middle East & Africa Adrenoleukodystrophy Treatment Market Size Growth (2018-2023)

5 AMERICAS

5.1 Americas Adrenoleukodystrophy Treatment Market Size by Country (2018-2023)
5.2 Americas Adrenoleukodystrophy Treatment Market Size by Type (2018-2023)
5.3 Americas Adrenoleukodystrophy Treatment Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Adrenoleukodystrophy Treatment Market Size by Region (2018-2023)
6.2 APAC Adrenoleukodystrophy Treatment Market Size by Type (2018-2023)
6.3 APAC Adrenoleukodystrophy Treatment Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia

7 EUROPE

7.1 Europe Adrenoleukodystrophy Treatment by Country (2018-2023)
7.2 Europe Adrenoleukodystrophy Treatment Market Size by Type (2018-2023)
7.3 Europe Adrenoleukodystrophy Treatment Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Adrenoleukodystrophy Treatment by Region (2018-2023)
8.2 Middle East & Africa Adrenoleukodystrophy Treatment Market Size by Type (2018-2023)
8.3 Middle East & Africa Adrenoleukodystrophy Treatment Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 GLOBAL ADRENOLEUKODYSTROPHY TREATMENT MARKET FORECAST

10.1 Global Adrenoleukodystrophy Treatment Forecast by Regions (2024-2029)
  10.1.1 Global Adrenoleukodystrophy Treatment Forecast by Regions (2024-2029)
  10.1.2 Americas Adrenoleukodystrophy Treatment Forecast
  10.1.3 APAC Adrenoleukodystrophy Treatment Forecast
  10.1.4 Europe Adrenoleukodystrophy Treatment Forecast
  10.1.5 Middle East & Africa Adrenoleukodystrophy Treatment Forecast
10.2 Americas Adrenoleukodystrophy Treatment Forecast by Country (2024-2029)
  10.2.1 United States Adrenoleukodystrophy Treatment Market Forecast
  10.2.2 Canada Adrenoleukodystrophy Treatment Market Forecast
  10.2.3 Mexico Adrenoleukodystrophy Treatment Market Forecast
  10.2.4 Brazil Adrenoleukodystrophy Treatment Market Forecast
10.3 APAC Adrenoleukodystrophy Treatment Forecast by Region (2024-2029)
  10.3.1 China Adrenoleukodystrophy Treatment Market Forecast
  10.3.2 Japan Adrenoleukodystrophy Treatment Market Forecast
  10.3.3 Korea Adrenoleukodystrophy Treatment Market Forecast
  10.3.4 Southeast Asia Adrenoleukodystrophy Treatment Market Forecast
  10.3.5 India Adrenoleukodystrophy Treatment Market Forecast
  10.3.6 Australia Adrenoleukodystrophy Treatment Market Forecast
10.4 Europe Adrenoleukodystrophy Treatment Forecast by Country (2024-2029)
  10.4.1 Germany Adrenoleukodystrophy Treatment Market Forecast
  10.4.2 France Adrenoleukodystrophy Treatment Market Forecast
  10.4.3 UK Adrenoleukodystrophy Treatment Market Forecast
  10.4.4 Italy Adrenoleukodystrophy Treatment Market Forecast
  10.4.5 Russia Adrenoleukodystrophy Treatment Market Forecast
10.5 Middle East & Africa Adrenoleukodystrophy Treatment Forecast by Region (2024-2029)
  10.5.1 Egypt Adrenoleukodystrophy Treatment Market Forecast
  10.5.2 South Africa Adrenoleukodystrophy Treatment Market Forecast
  10.5.3 Israel Adrenoleukodystrophy Treatment Market Forecast
  10.5.4 Turkey Adrenoleukodystrophy Treatment Market Forecast
  10.5.5 GCC Countries Adrenoleukodystrophy Treatment Market Forecast
10.6 Global Adrenoleukodystrophy Treatment Forecast by Type (2024-2029)
10.7 Global Adrenoleukodystrophy Treatment Forecast by Application (2024-2029)

11 KEY PLAYERS ANALYSIS

11.1 bluebird bio
  11.1.1 bluebird bio Company Information
  11.1.2 bluebird bio Adrenoleukodystrophy Treatment Product Offered
  11.1.3 bluebird bio Adrenoleukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)
  11.1.4 bluebird bio Main Business Overview
  11.1.5 bluebird bio Latest Developments
11.2 Orpheris
  11.2.1 Orpheris Company Information
  11.2.2 Orpheris Adrenoleukodystrophy Treatment Product Offered
  11.2.3 Orpheris Adrenoleukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)
  11.2.4 Orpheris Main Business Overview
  11.2.5 Orpheris Latest Developments
11.3 MedDay Pharmaceuticals
  11.3.1 MedDay Pharmaceuticals Company Information
  11.3.2 MedDay Pharmaceuticals Adrenoleukodystrophy Treatment Product Offered
  11.3.3 MedDay Pharmaceuticals Adrenoleukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)
  11.3.4 MedDay Pharmaceuticals Main Business Overview
  11.3.5 MedDay Pharmaceuticals Latest Developments
11.4 MINORYX THERAPEUTICS SL
  11.4.1 MINORYX THERAPEUTICS SL Company Information
  11.4.2 MINORYX THERAPEUTICS SL Adrenoleukodystrophy Treatment Product Offered
  11.4.3 MINORYX THERAPEUTICS SL Adrenoleukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)
  11.4.4 MINORYX THERAPEUTICS SL Main Business Overview
  11.4.5 MINORYX THERAPEUTICS SL Latest Developments
11.5 Pfizer
  11.5.1 Pfizer Company Information
  11.5.2 Pfizer Adrenoleukodystrophy Treatment Product Offered
  11.5.3 Pfizer Adrenoleukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)
  11.5.4 Pfizer Main Business Overview
  11.5.5 Pfizer Latest Developments
11.6 Amgen
  11.6.1 Amgen Company Information
  11.6.2 Amgen Adrenoleukodystrophy Treatment Product Offered
  11.6.3 Amgen Adrenoleukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)
  11.6.4 Amgen Main Business Overview
  11.6.5 Amgen Latest Developments
11.7 AstraZeneca
  11.7.1 AstraZeneca Company Information
  11.7.2 AstraZeneca Adrenoleukodystrophy Treatment Product Offered
  11.7.3 AstraZeneca Adrenoleukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)
  11.7.4 AstraZeneca Main Business Overview
  11.7.5 AstraZeneca Latest Developments
11.8 Abbott
  11.8.1 Abbott Company Information
  11.8.2 Abbott Adrenoleukodystrophy Treatment Product Offered
  11.8.3 Abbott Adrenoleukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)
  11.8.4 Abbott Main Business Overview
  11.8.5 Abbott Latest Developments
11.9 agtc
  11.9.1 agtc Company Information
  11.9.2 agtc Adrenoleukodystrophy Treatment Product Offered
  11.9.3 agtc Adrenoleukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)
  11.9.4 agtc Main Business Overview
  11.9.5 agtc Latest Developments
11.10 ReceptoPharm
  11.10.1 ReceptoPharm Company Information
  11.10.2 ReceptoPharm Adrenoleukodystrophy Treatment Product Offered
  11.10.3 ReceptoPharm Adrenoleukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)
  11.10.4 ReceptoPharm Main Business Overview
  11.10.5 ReceptoPharm Latest Developments
11.11 The Myelin Project
  11.11.1 The Myelin Project Company Information
  11.11.2 The Myelin Project Adrenoleukodystrophy Treatment Product Offered
  11.11.3 The Myelin Project Adrenoleukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)
  11.11.4 The Myelin Project Main Business Overview
  11.11.5 The Myelin Project Latest Developments
11.12 SOM Biotech
  11.12.1 SOM Biotech Company Information
  11.12.2 SOM Biotech Adrenoleukodystrophy Treatment Product Offered
  11.12.3 SOM Biotech Adrenoleukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)
  11.12.4 SOM Biotech Main Business Overview
  11.12.5 SOM Biotech Latest Developments
11.13 Viking Therapeutics
  11.13.1 Viking Therapeutics Company Information
  11.13.2 Viking Therapeutics Adrenoleukodystrophy Treatment Product Offered
  11.13.3 Viking Therapeutics Adrenoleukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)
  11.13.4 Viking Therapeutics Main Business Overview
  11.13.5 Viking Therapeutics Latest Developments
11.14 Nutra Pharma Corporation
  11.14.1 Nutra Pharma Corporation Company Information
  11.14.2 Nutra Pharma Corporation Adrenoleukodystrophy Treatment Product Offered
  11.14.3 Nutra Pharma Corporation Adrenoleukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)
  11.14.4 Nutra Pharma Corporation Main Business Overview
  11.14.5 Nutra Pharma Corporation Latest Developments
11.15 Genetix Biotech
  11.15.1 Genetix Biotech Company Information
  11.15.2 Genetix Biotech Adrenoleukodystrophy Treatment Product Offered
  11.15.3 Genetix Biotech Adrenoleukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)
  11.15.4 Genetix Biotech Main Business Overview
  11.15.5 Genetix Biotech Latest Developments
11.16 Magenta Therapeutics
  11.16.1 Magenta Therapeutics Company Information
  11.16.2 Magenta Therapeutics Adrenoleukodystrophy Treatment Product Offered
  11.16.3 Magenta Therapeutics Adrenoleukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)
  11.16.4 Magenta Therapeutics Main Business Overview
  11.16.5 Magenta Therapeutics Latest Developments
11.17 NeuroVia
  11.17.1 NeuroVia Company Information
  11.17.2 NeuroVia Adrenoleukodystrophy Treatment Product Offered
  11.17.3 NeuroVia Adrenoleukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)
  11.17.4 NeuroVia Main Business Overview
  11.17.5 NeuroVia Latest Developments
11.18 Novartis
  11.18.1 Novartis Company Information
  11.18.2 Novartis Adrenoleukodystrophy Treatment Product Offered
  11.18.3 Novartis Adrenoleukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)
  11.18.4 Novartis Main Business Overview
  11.18.5 Novartis Latest Developments
11.19 CELGENE CORPORATION
  11.19.1 CELGENE CORPORATION Company Information
  11.19.2 CELGENE CORPORATION Adrenoleukodystrophy Treatment Product Offered
  11.19.3 CELGENE CORPORATION Adrenoleukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)
  11.19.4 CELGENE CORPORATION Main Business Overview
  11.19.5 CELGENE CORPORATION Latest Developments
11.20 Jazz Pharmaceuticals
  11.20.1 Jazz Pharmaceuticals Company Information
  11.20.2 Jazz Pharmaceuticals Adrenoleukodystrophy Treatment Product Offered
  11.20.3 Jazz Pharmaceuticals Adrenoleukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)
  11.20.4 Jazz Pharmaceuticals Main Business Overview
  11.20.5 Jazz Pharmaceuticals Latest Developments
11.21 Sanofi
  11.21.1 Sanofi Company Information
  11.21.2 Sanofi Adrenoleukodystrophy Treatment Product Offered
  11.21.3 Sanofi Adrenoleukodystrophy Treatment Revenue, Gross Margin and Market Share (2018-2023)
  11.21.4 Sanofi Main Business Overview
  11.21.5 Sanofi Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES

Table 1. Adrenoleukodystrophy Treatment Market Size CAGR by Region (2018 VS 2022 VS 2029) & ($ Millions)
Table 2. Major Players of Oral Drugs
Table 3. Major Players of Parenteral Drugs
Table 4. Adrenoleukodystrophy Treatment Market Size CAGR by Type (2018 VS 2022 VS 2029) & ($ Millions)
Table 5. Global Adrenoleukodystrophy Treatment Market Size by Type (2018-2023) & ($ Millions)
Table 6. Global Adrenoleukodystrophy Treatment Market Size Market Share by Type (2018-2023)
Table 7. Adrenoleukodystrophy Treatment Market Size CAGR by Application (2018 VS 2022 VS 2029) & ($ Millions)
Table 8. Global Adrenoleukodystrophy Treatment Market Size by Application (2018-2023) & ($ Millions)
Table 9. Global Adrenoleukodystrophy Treatment Market Size Market Share by Application (2018-2023)
Table 10. Global Adrenoleukodystrophy Treatment Revenue by Players (2018-2023) & ($ Millions)
Table 11. Global Adrenoleukodystrophy Treatment Revenue Market Share by Player (2018-2023)
Table 12. Adrenoleukodystrophy Treatment Key Players Head office and Products Offered
Table 13. Adrenoleukodystrophy Treatment Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
Table 14. New Products and Potential Entrants
Table 15. Mergers & Acquisitions, Expansion
Table 16. Global Adrenoleukodystrophy Treatment Market Size by Regions 2018-2023 & ($ Millions)
Table 17. Global Adrenoleukodystrophy Treatment Market Size Market Share by Regions (2018-2023)
Table 18. Global Adrenoleukodystrophy Treatment Revenue by Country/Region (2018-2023) & ($ millions)
Table 19. Global Adrenoleukodystrophy Treatment Revenue Market Share by Country/Region (2018-2023)
Table 20. Americas Adrenoleukodystrophy Treatment Market Size by Country (2018-2023) & ($ Millions)
Table 21. Americas Adrenoleukodystrophy Treatment Market Size Market Share by Country (2018-2023)
Table 22. Americas Adrenoleukodystrophy Treatment Market Size by Type (2018-2023) & ($ Millions)
Table 23. Americas Adrenoleukodystrophy Treatment Market Size Market Share by Type (2018-2023)
Table 24. Americas Adrenoleukodystrophy Treatment Market Size by Application (2018-2023) & ($ Millions)
Table 25. Americas Adrenoleukodystrophy Treatment Market Size Market Share by Application (2018-2023)
Table 26. APAC Adrenoleukodystrophy Treatment Market Size by Region (2018-2023) & ($ Millions)
Table 27. APAC Adrenoleukodystrophy Treatment Market Size Market Share by Region (2018-2023)
Table 28. APAC Adrenoleukodystrophy Treatment Market Size by Type (2018-2023) & ($ Millions)
Table 29. APAC Adrenoleukodystrophy Treatment Market Size Market Share by Type (2018-2023)
Table 30. APAC Adrenoleukodystrophy Treatment Market Size by Application (2018-2023) & ($ Millions)
Table 31. APAC Adrenoleukodystrophy Treatment Market Size Market Share by Application (2018-2023)
Table 32. Europe Adrenoleukodystrophy Treatment Market Size by Country (2018-2023) & ($ Millions)
Table 33. Europe Adrenoleukodystrophy Treatment Market Size Market Share by Country (2018-2023)
Table 34. Europe Adrenoleukodystrophy Treatment Market Size by Type (2018-2023) & ($ Millions)
Table 35. Europe Adrenoleukodystrophy Treatment Market Size Market Share by Type (2018-2023)
Table 36. Europe Adrenoleukodystrophy Treatment Market Size by Application (2018-2023) & ($ Millions)
Table 37. Europe Adrenoleukodystrophy Treatment Market Size Market Share by Application (2018-2023)
Table 38. Middle East & Africa Adrenoleukodystrophy Treatment Market Size by Region (2018-2023) & ($ Millions)
Table 39. Middle East & Africa Adrenoleukodystrophy Treatment Market Size Market Share by Region (2018-2023)
Table 40. Middle East & Africa Adrenoleukodystrophy Treatment Market Size by Type (2018-2023) & ($ Millions)
Table 41. Middle East & Africa Adrenoleukodystrophy Treatment Market Size Market Share by Type (2018-2023)
Table 42. Middle East & Africa Adrenoleukodystrophy Treatment Market Size by Application (2018-2023) & ($ Millions)
Table 43. Middle East & Africa Adrenoleukodystrophy Treatment Market Size Market Share by Application (2018-2023)
Table 44. Key Market Drivers & Growth Opportunities of Adrenoleukodystrophy Treatment
Table 45. Key Market Challenges & Risks of Adrenoleukodystrophy Treatment
Table 46. Key Industry Trends of Adrenoleukodystrophy Treatment
Table 47. Global Adrenoleukodystrophy Treatment Market Size Forecast by Regions (2024-2029) & ($ Millions)
Table 48. Global Adrenoleukodystrophy Treatment Market Size Market Share Forecast by Regions (2024-2029)
Table 49. Global Adrenoleukodystrophy Treatment Market Size Forecast by Type (2024-2029) & ($ Millions)
Table 50. Global Adrenoleukodystrophy Treatment Market Size Forecast by Application (2024-2029) & ($ Millions)
Table 51. bluebird bio Details, Company Type, Adrenoleukodystrophy Treatment Area Served and Its Competitors
Table 52. bluebird bio Adrenoleukodystrophy Treatment Product Offered
Table 53. bluebird bio Adrenoleukodystrophy Treatment Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 54. bluebird bio Main Business
Table 55. bluebird bio Latest Developments
Table 56. Orpheris Details, Company Type, Adrenoleukodystrophy Treatment Area Served and Its Competitors
Table 57. Orpheris Adrenoleukodystrophy Treatment Product Offered
Table 58. Orpheris Main Business
Table 59. Orpheris Adrenoleukodystrophy Treatment Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 60. Orpheris Latest Developments
Table 61. MedDay Pharmaceuticals Details, Company Type, Adrenoleukodystrophy Treatment Area Served and Its Competitors
Table 62. MedDay Pharmaceuticals Adrenoleukodystrophy Treatment Product Offered
Table 63. MedDay Pharmaceuticals Main Business
Table 64. MedDay Pharmaceuticals Adrenoleukodystrophy Treatment Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 65. MedDay Pharmaceuticals Latest Developments
Table 66. MINORYX THERAPEUTICS SL Details, Company Type, Adrenoleukodystrophy Treatment Area Served and Its Competitors
Table 67. MINORYX THERAPEUTICS SL Adrenoleukodystrophy Treatment Product Offered
Table 68. MINORYX THERAPEUTICS SL Main Business
Table 69. MINORYX THERAPEUTICS SL Adrenoleukodystrophy Treatment Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 70. MINORYX THERAPEUTICS SL Latest Developments
Table 71. Pfizer Details, Company Type, Adrenoleukodystrophy Treatment Area Served and Its Competitors
Table 72. Pfizer Adrenoleukodystrophy Treatment Product Offered
Table 73. Pfizer Main Business
Table 74. Pfizer Adrenoleukodystrophy Treatment Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 75. Pfizer Latest Developments
Table 76. Amgen Details, Company Type, Adrenoleukodystrophy Treatment Area Served and Its Competitors
Table 77. Amgen Adrenoleukodystrophy Treatment Product Offered
Table 78. Amgen Main Business
Table 79. Amgen Adrenoleukodystrophy Treatment Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 80. Amgen Latest Developments
Table 81. AstraZeneca Details, Company Type, Adrenoleukodystrophy Treatment Area Served and Its Competitors
Table 82. AstraZeneca Adrenoleukodystrophy Treatment Product Offered
Table 83. AstraZeneca Main Business
Table 84. AstraZeneca Adrenoleukodystrophy Treatment Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 85. AstraZeneca Latest Developments
Table 86. Abbott Details, Company Type, Adrenoleukodystrophy Treatment Area Served and Its Competitors
Table 87. Abbott Adrenoleukodystrophy Treatment Product Offered
Table 88. Abbott Main Business
Table 89. Abbott Adrenoleukodystrophy Treatment Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 90. Abbott Latest Developments
Table 91. agtc Details, Company Type, Adrenoleukodystrophy Treatment Area Served and Its Competitors
Table 92. agtc Adrenoleukodystrophy Treatment Product Offered
Table 93. agtc Main Business
Table 94. agtc Adrenoleukodystrophy Treatment Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 95. agtc Latest Developments
Table 96. ReceptoPharm Details, Company Type, Adrenoleukodystrophy Treatment Area Served and Its Competitors
Table 97. ReceptoPharm Adrenoleukodystrophy Treatment Product Offered
Table 98. ReceptoPharm Main Business
Table 99. ReceptoPharm Adrenoleukodystrophy Treatment Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 100. ReceptoPharm Latest Developments
Table 101. The Myelin Project Details, Company Type, Adrenoleukodystrophy Treatment Area Served and Its Competitors
Table 102. The Myelin Project Adrenoleukodystrophy Treatment Product Offered
Table 103. The Myelin Project Adrenoleukodystrophy Treatment Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 104. The Myelin Project Main Business
Table 105. The Myelin Project Latest Developments
Table 106. SOM Biotech Details, Company Type, Adrenoleukodystrophy Treatment Area Served and Its Competitors
Table 107. SOM Biotech Adrenoleukodystrophy Treatment Product Offered
Table 108. SOM Biotech Main Business
Table 109. SOM Biotech Adrenoleukodystrophy Treatment Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 110. SOM Biotech Latest Developments
Table 111. Viking Therapeutics Details, Company Type, Adrenoleukodystrophy Treatment Area Served and Its Competitors
Table 112. Viking Therapeutics Adrenoleukodystrophy Treatment Product Offered
Table 113. Viking Therapeutics Main Business
Table 114. Viking Therapeutics Adrenoleukodystrophy Treatment Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 115. Viking Therapeutics Latest Developments
Table 116. Nutra Pharma Corporation Details, Company Type, Adrenoleukodystrophy Treatment Area Served and Its Competitors
Table 117. Nutra Pharma Corporation Adrenoleukodystrophy Treatment Product Offered
Table 118. Nutra Pharma Corporation Main Business
Table 119. Nutra Pharma Corporation Adrenoleukodystrophy Treatment Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 120. Nutra Pharma Corporation Latest Developments
Table 121. Genetix Biotech Details, Company Type, Adrenoleukodystrophy Treatment Area Served and Its Competitors
Table 122. Genetix Biotech Adrenoleukodystrophy Treatment Product Offered
Table 123. Genetix Biotech Main Business
Table 124. Genetix Biotech Adrenoleukodystrophy Treatment Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 125. Genetix Biotech Latest Developments
Table 126. Magenta Therapeutics Details, Company Type, Adrenoleukodystrophy Treatment Area Served and Its Competitors
Table 127. Magenta Therapeutics Adrenoleukodystrophy Treatment Product Offered
Table 128. Magenta Therapeutics Main Business
Table 129. Magenta Therapeutics Adrenoleukodystrophy Treatment Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 130. Magenta Therapeutics Latest Developments
Table 131. NeuroVia Details, Company Type, Adrenoleukodystrophy Treatment Area Served and Its Competitors
Table 132. NeuroVia Adrenoleukodystrophy Treatment Product Offered
Table 133. NeuroVia Main Business
Table 134. NeuroVia Adrenoleukodystrophy Treatment Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 135. NeuroVia Latest Developments
Table 136. Novartis Details, Company Type, Adrenoleukodystrophy Treatment Area Served and Its Competitors
Table 137. Novartis Adrenoleukodystrophy Treatment Product Offered
Table 138. Novartis Main Business
Table 139. Novartis Adrenoleukodystrophy Treatment Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 140. Novartis Latest Developments
Table 141. CELGENE CORPORATION Details, Company Type, Adrenoleukodystrophy Treatment Area Served and Its Competitors
Table 142. CELGENE CORPORATION Adrenoleukodystrophy Treatment Product Offered
Table 143. CELGENE CORPORATION Main Business
Table 144. CELGENE CORPORATION Adrenoleukodystrophy Treatment Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 145. CELGENE CORPORATION Latest Developments
Table 146. Jazz Pharmaceuticals Details, Company Type, Adrenoleukodystrophy Treatment Area Served and Its Competitors
Table 147. Jazz Pharmaceuticals Adrenoleukodystrophy Treatment Product Offered
Table 148. Jazz Pharmaceuticals Main Business
Table 149. Jazz Pharmaceuticals Adrenoleukodystrophy Treatment Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 150. Jazz Pharmaceuticals Latest Developments
Table 151. Sanofi Details, Company Type, Adrenoleukodystrophy Treatment Area Served and Its Competitors
Table 152. Sanofi Adrenoleukodystrophy Treatment Product Offered
Table 153. Sanofi Adrenoleukodystrophy Treatment Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 154. Sanofi Main Business
Table 155. Sanofi Latest Developments

LIST OF FIGURES

Figure 1. Adrenoleukodystrophy Treatment Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Adrenoleukodystrophy Treatment Market Size Growth Rate 2018-2029 ($ Millions)
Figure 6. Adrenoleukodystrophy Treatment Sales by Geographic Region (2018, 2022 & 2029) & ($ millions)
Figure 7. Adrenoleukodystrophy Treatment Sales Market Share by Country/Region (2022)
Figure 8. Adrenoleukodystrophy Treatment Sales Market Share by Country/Region (2018, 2022 & 2029)
Figure 9. Global Adrenoleukodystrophy Treatment Market Size Market Share by Type in 2022
Figure 10. Adrenoleukodystrophy Treatment in Hospital
Figure 11. Global Adrenoleukodystrophy Treatment Market: Hospital (2018-2023) & ($ Millions)
Figure 12. Adrenoleukodystrophy Treatment in Clinic
Figure 13. Global Adrenoleukodystrophy Treatment Market: Clinic (2018-2023) & ($ Millions)
Figure 14. Adrenoleukodystrophy Treatment in Home Care
Figure 15. Global Adrenoleukodystrophy Treatment Market: Home Care (2018-2023) & ($ Millions)
Figure 16. Global Adrenoleukodystrophy Treatment Market Size Market Share by Application in 2022
Figure 17. Global Adrenoleukodystrophy Treatment Revenue Market Share by Player in 2022
Figure 18. Global Adrenoleukodystrophy Treatment Market Size Market Share by Regions (2018-2023)
Figure 19. Americas Adrenoleukodystrophy Treatment Market Size 2018-2023 ($ Millions)
Figure 20. APAC Adrenoleukodystrophy Treatment Market Size 2018-2023 ($ Millions)
Figure 21. Europe Adrenoleukodystrophy Treatment Market Size 2018-2023 ($ Millions)
Figure 22. Middle East & Africa Adrenoleukodystrophy Treatment Market Size 2018-2023 ($ Millions)
Figure 23. Americas Adrenoleukodystrophy Treatment Value Market Share by Country in 2022
Figure 24. United States Adrenoleukodystrophy Treatment Market Size Growth 2018-2023 ($ Millions)
Figure 25. Canada Adrenoleukodystrophy Treatment Market Size Growth 2018-2023 ($ Millions)
Figure 26. Mexico Adrenoleukodystrophy Treatment Market Size Growth 2018-2023 ($ Millions)
Figure 27. Brazil Adrenoleukodystrophy Treatment Market Size Growth 2018-2023 ($ Millions)
Figure 28. APAC Adrenoleukodystrophy Treatment Market Size Market Share by Region in 2022
Figure 29. APAC Adrenoleukodystrophy Treatment Market Size Market Share by Type in 2022
Figure 30. APAC Adrenoleukodystrophy Treatment Market Size Market Share by Application in 2022
Figure 31. China Adrenoleukodystrophy Treatment Market Size Growth 2018-2023 ($ Millions)
Figure 32. Japan Adrenoleukodystrophy Treatment Market Size Growth 2018-2023 ($ Millions)
Figure 33. Korea Adrenoleukodystrophy Treatment Market Size Growth 2018-2023 ($ Millions)
Figure 34. Southeast Asia Adrenoleukodystrophy Treatment Market Size Growth 2018-2023 ($ Millions)
Figure 35. India Adrenoleukodystrophy Treatment Market Size Growth 2018-2023 ($ Millions)
Figure 36. Australia Adrenoleukodystrophy Treatment Market Size Growth 2018-2023 ($ Millions)
Figure 37. Europe Adrenoleukodystrophy Treatment Market Size Market Share by Country in 2022
Figure 38. Europe Adrenoleukodystrophy Treatment Market Size Market Share by Type (2018-2023)
Figure 39. Europe Adrenoleukodystrophy Treatment Market Size Market Share by Application (2018-2023)
Figure 40. Germany Adrenoleukodystrophy Treatment Market Size Growth 2018-2023 ($ Millions)
Figure 41. France Adrenoleukodystrophy Treatment Market Size Growth 2018-2023 ($ Millions)
Figure 42. UK Adrenoleukodystrophy Treatment Market Size Growth 2018-2023 ($ Millions)
Figure 43. Italy Adrenoleukodystrophy Treatment Market Size Growth 2018-2023 ($ Millions)
Figure 44. Russia Adrenoleukodystrophy Treatment Market Size Growth 2018-2023 ($ Millions)
Figure 45. Middle East & Africa Adrenoleukodystrophy Treatment Market Size Market Share by Region (2018-2023)
Figure 46. Middle East & Africa Adrenoleukodystrophy Treatment Market Size Market Share by Type (2018-2023)
Figure 47. Middle East & Africa Adrenoleukodystrophy Treatment Market Size Market Share by Application (2018-2023)
Figure 48. Egypt Adrenoleukodystrophy Treatment Market Size Growth 2018-2023 ($ Millions)
Figure 49. South Africa Adrenoleukodystrophy Treatment Market Size Growth 2018-2023 ($ Millions)
Figure 50. Israel Adrenoleukodystrophy Treatment Market Size Growth 2018-2023 ($ Millions)
Figure 51. Turkey Adrenoleukodystrophy Treatment Market Size Growth 2018-2023 ($ Millions)
Figure 52. GCC Country Adrenoleukodystrophy Treatment Market Size Growth 2018-2023 ($ Millions)
Figure 53. Americas Adrenoleukodystrophy Treatment Market Size 2024-2029 ($ Millions)
Figure 54. APAC Adrenoleukodystrophy Treatment Market Size 2024-2029 ($ Millions)
Figure 55. Europe Adrenoleukodystrophy Treatment Market Size 2024-2029 ($ Millions)
Figure 56. Middle East & Africa Adrenoleukodystrophy Treatment Market Size 2024-2029 ($ Millions)
Figure 57. United States Adrenoleukodystrophy Treatment Market Size 2024-2029 ($ Millions)
Figure 58. Canada Adrenoleukodystrophy Treatment Market Size 2024-2029 ($ Millions)
Figure 59. Mexico Adrenoleukodystrophy Treatment Market Size 2024-2029 ($ Millions)
Figure 60. Brazil Adrenoleukodystrophy Treatment Market Size 2024-2029 ($ Millions)
Figure 61. China Adrenoleukodystrophy Treatment Market Size 2024-2029 ($ Millions)
Figure 62. Japan Adrenoleukodystrophy Treatment Market Size 2024-2029 ($ Millions)
Figure 63. Korea Adrenoleukodystrophy Treatment Market Size 2024-2029 ($ Millions)
Figure 64. Southeast Asia Adrenoleukodystrophy Treatment Market Size 2024-2029 ($ Millions)
Figure 65. India Adrenoleukodystrophy Treatment Market Size 2024-2029 ($ Millions)
Figure 66. Australia Adrenoleukodystrophy Treatment Market Size 2024-2029 ($ Millions)
Figure 67. Germany Adrenoleukodystrophy Treatment Market Size 2024-2029 ($ Millions)
Figure 68. France Adrenoleukodystrophy Treatment Market Size 2024-2029 ($ Millions)
Figure 69. UK Adrenoleukodystrophy Treatment Market Size 2024-2029 ($ Millions)
Figure 70. Italy Adrenoleukodystrophy Treatment Market Size 2024-2029 ($ Millions)
Figure 71. Russia Adrenoleukodystrophy Treatment Market Size 2024-2029 ($ Millions)
Figure 72. Spain Adrenoleukodystrophy Treatment Market Size 2024-2029 ($ Millions)
Figure 73. Egypt Adrenoleukodystrophy Treatment Market Size 2024-2029 ($ Millions)
Figure 74. South Africa Adrenoleukodystrophy Treatment Market Size 2024-2029 ($ Millions)
Figure 75. Israel Adrenoleukodystrophy Treatment Market Size 2024-2029 ($ Millions)
Figure 76. Turkey Adrenoleukodystrophy Treatment Market Size 2024-2029 ($ Millions)
Figure 77. GCC Countries Adrenoleukodystrophy Treatment Market Size 2024-2029 ($ Millions)
Figure 78. Global Adrenoleukodystrophy Treatment Market Size Market Share Forecast by Type (2024-2029)
Figure 79. Global Adrenoleukodystrophy Treatment Market Size Market Share Forecast by Application (2024-2029)


More Publications